The collaborative investigation centered on the role of CD4+ T cells—critical players in the immune system’s adaptive response—in patients afflicted with ALS. These immune cells were found to aberrantly target C9orf72, a protein highly expressed in neurons, effectively marking the nervous system as a target for immune-mediated attack. This self-reactivity underscores a fundamental characteristic of autoimmune diseases, where the body’s defense system erroneously recognizes its own proteins as foreign invaders.

Alessandro Sette, Ph.D., a co-lead on the study from the LJI, emphasized the novelty of these findings: “For the first time, we have unequivocal evidence demonstrating that ALS involves an autoimmune response targeting specific neuronal proteins.” Partnering with Columbia’s David Sulzer, Ph.D., the team used advanced immunological assays to detect heightened levels of inflammation-promoting CD4+ T cells in ALS patients, specifically those reactive against the C9orf72 protein. This discovery shifts the paradigm of ALS research by implicating immune dysregulation as a central contributor to disease pathology.

Surprisingly, the research delineated two distinct subpopulations among ALS patients based on their immune profiles. One subset exhibited highly inflammatory CD4+ T cell responses to C9orf72, correlating with shorter predicted survival times. Conversely, a second group demonstrated a more balanced immune signature, characterized by both inflammatory and regulatory, or anti-inflammatory, CD4+ T cells. These regulatory cells are paramount in mitigating excessive immune activation, thereby potentially slowing neuronal degradation and extending patient longevity.

This immunological dichotomy offers a plausible explanation for the perplexing heterogeneity in ALS progression. Notably, public figures such as Lou Gehrig succumbed rapidly to the disease, while others like Stephen Hawking defied odds by surviving for decades post-diagnosis. The newly identified protective role of regulatory CD4+ T cells suggests that modulating these immune components could become a strategic therapeutic avenue to prolong survival and enhance quality of life for ALS patients.

Further mechanistic insights reveal that under normal circumstances, the immune system balances aggressive responses to eliminate pathogens with counteracting signals that restrain immune activity, thus preserving healthy tissue integrity. ALS patients with longer survival times appear to maintain this delicate immunological equilibrium, where anti-inflammatory T cells temper the destructive potential of their inflammatory counterparts.

Looking forward, the research community anticipates harnessing these insights to develop targeted immunotherapies aimed at augmenting regulatory CD4+ T cell responses while damping harmful inflammation in ALS. Tanner Michaelis, the study’s first author and LJI research technician, highlighted the potential impact of these findings: “Identifying C9orf72 as a specific immune target opens new horizons for treatment strategies that are far more precise than current approaches.”

Moreover, the implications of this research transcend ALS, with co-leader Alessandro Sette proposing that similar autoimmune phenomena may underpin other neurodegenerative disorders, including Parkinson’s, Huntington’s, and Alzheimer’s diseases. This aligns with the emergent field of neuroimmunology, where accumulating evidence implicates immune components in the pathogenesis of multiple neurologic conditions previously thought to be purely degenerative.

The study builds on prior discoveries from the Sette Laboratory that connected autoimmunity and Parkinson’s disease, reinforcing the concept that immune dysregulation is a common denominator in neurodegeneration. Sette stated, “The involvement of immune cells in neurodegenerative diseases is becoming more of a rule than an exception, fundamentally altering our understanding of these pathologies and opening avenues for immune-based interventions.”

This landmark work was recently published in the prestigious journal Nature, signifying a major milestone in neuroimmune research. It was supported by multiple funding sources, including LJI & Kyowa Kirin, the Swedish Research Council, the Freedom Together Foundation, and the National Institute of Neurological Disorders and Stroke, underscoring the broad scientific interest and significance of these findings.

As the field advances, researchers remain cautious yet optimistic, recognizing that translating these discoveries into clinical therapies will necessitate rigorous testing and validation. Nonetheless, the identification of a direct autoimmune response against a neuronal protein in ALS patients marks a paradigm shift that promises to transform diagnostic and therapeutic approaches, offering renewed hope for patients facing this relentless disease.

Subject of Research: Cells
Article Title: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis
News Publication Date: October 1, 2025
Web References: http://dx.doi.org/10.1038/s41586-025-09588-6
References: Alessandro Sette, David Sulzer et al., Nature, 2025
Image Credits: La Jolla Institute for Immunology
Keywords: Neuroscience; Immunogenetics; Immunology; Immune cells; Effector cells; Effector T cells; Immune disorders; Autoimmune disorders; Antigens; Neoantigens; Immune response; Adaptive immune response; T cell activation; Immunoreactivity; Neurons; Amyotrophic lateral sclerosis; Neurological disorders; Neurodegenerative diseases; Neuropathology; Diseases and disorders; Human health; Human biology

Dengue virus, endemic in many tropical and subtropical regions, affects nearly 400 million people annually. Unfortunately, it leads to significant morbidity and mortality across affected populations. With four distinct serotypes of the virus, exposure to one serotype can complicate subsequent infections with another, often leading to heightened risks of severe disease. Most alarming is the fact that there are currently few vaccines available, and no approved therapies exist for dengue, highlighting the urgent need for more research in this domain.

Published in the esteemed journal JCI Insight, the findings indicate that most children who suffered two or more infections exhibit minor or no symptoms during subsequent exposures to the virus. This phenomenon suggests a possible immunological memory—the body’s way of recalling previous encounters with a pathogen—to mitigate severe illness from future infections. Leading the investigation, LJI Assistant Professor Daniela Weiskopf, Ph.D., emphasizes the correlation between T cell proliferation and infection outcomes, providing crucial insights into how immunity develops in pediatric populations.

The study involved a thorough examination of 71 children in Managua, Nicaragua, a region endemic for dengue virus. This unique strategy utilized blood samples to identify the presence of antibodies against dengue, providing essential data on infection history. A critical component of the research included recognizing inapparent cases, where children had been exposed to the virus yet displayed no clinical symptoms—underscoring the complexity of immune responses.

Researchers observed that the incidence of dengue-specific T cells increased with each infection, appearing to correspond to better health outcomes in affected children. The critical question explored in the study was whether T cells were beneficial or harmful during the fight against the virus. While a weak T cell response can be detrimental, leading to ineffective pathogen clearance, an overwhelming response can cause inflammation and severe complications, creating a delicate balance for the immune system to manage.

Children participating in the study ranged from ages two to seventeen, highlighting the varied immune responses across different developmental stages. Regular monitoring of these children’s immune profiles allowed scientists to discern patterns in seroconversion, which indicates that multiple exposures to dengue could lead to enhanced immune capabilities through T cell expansion.

A particularly intriguing aspect of this work is its potential implications for vaccine development. Currently, the FDA has approved Dengvaxia, a vaccine targeting dengue, mainly for those aged 9 to 16 with prior exposure to the virus. However, the vaccine has been met with challenges, especially regarding its effectiveness in individuals without a history of dengue infection. The current research findings strongly suggest that T cells’ readiness to respond is a crucial factor in immunity, proposing a need for future vaccine strategies that ensure T cell activation upon first exposure.

The expanding territory of dengue-carrying mosquitoes into new geographical areas, such as Southern California, raises further concerns about the risk of dengue outbreaks in regions where populations have not been previously exposed. In fact, California reported its first-ever case of locally acquired dengue in 2023, followed by confirmed cases across Los Angeles and San Diego County. These developments underline the urgency for public health officials to understand dengue’s re-emergence and implement effective prevention strategies.

The study also highlights the contributions of global collaborative research, specifically citing Eva Harris, Ph.D., of UC Berkeley, who has a longstanding partnership with Nicaraguan scientists. Such international efforts are invaluable as dengue continues to affect populations worldwide. They can potentially uncover the nuances of immune reactions in diverse demographics, advancing global efforts to combat vector-borne diseases.

The investigation involved rigorous methodologies to delineate the role of T cells in causing or mitigating symptoms during dengue infections. It reaffirmed the premise that previous exposure could, indeed, lead to a more tempered immune reaction where children are less prone to severe illness. This finding not only provides hope for understanding dengue immunity but also lays the groundwork for future vaccine developments that foster similar protective responses.

In conclusion, the insights gained from this study may revolutionize our understanding of vaccine development, particularly for diseases like dengue, where exposure history can significantly alter immunity outcomes. While a long road lies ahead, the results serve as a clarion call to public health and immunology communities to harness the power of T cells in designing effective immunization strategies.

As dengue’s geographic reach expands, the urgency to develop an effective vaccine that can harness the body’s immune responses amplifies. With ongoing research, scientists hope to unlock the intricacies of T cell responses to deliver next-generation vaccines that protect populations at risk while expanding our understanding of the immune landscape in response to viral infections.

In this regard, the scientific community is urged to continue investigating the complexities of T cell responses and their implications in vaccine formulations. The work done by Weiskopf and her colleagues certainly marks an important milestone in the ongoing battle against dengue virus but also serves as motivation for future endeavors in immunology and vaccine innovation.

Subject of Research: T cell responses to dengue virus
Article Title: Frequency of dengue virus-specific T cells is related to infection outcome in endemic settings
News Publication Date: 24-Feb-2025
Web References: https://insight.jci.org/articles/view/179771
References: DOI: 10.1172/jci.insight.179771
Image Credits: Credit: La Jolla Institute for Immunology
Keywords: T cells, dengue virus, immunology, vaccine development, pediatric infections, global health, serotypes, immune response, public health, vector-borne diseases.